DermWire | Newest Articles http://practicaldermatology.com/dermwire/ Newest Articles en-us Tue, 26 Sep 2017 00:01:48 GMT Tue, 26 Sep 2017 00:01:48 GMT DermWire Sciton and the Young Survival Coalition Partner for Breast Cancer Awareness http://practicaldermatology.com/dermwire/view.asp?url=sciton-and-the-young-survival-coalition-partner-for-breast-cancer-awareness Sciton, Inc.’s Women's Health Group division and the Young Survival Coalition (YSC) are partnering to raise awareness about women's vaginal health, in particular, those who are recovering from breast cancer therapy. The Project Pink diVa starts with manufacturing new bright pink diVa handpieces for new diVa providers. Sciton will also be donating 5 percent of each diVa module and each Strengthened Quartz Dilator during October and November 2017 to the Young Survival Coalition, w… Mon, 25 Sep 2017 04:00:00 GMT Dr. Michael H. Gold Joins AIVITA Scientific Advisory Board http://practicaldermatology.com/dermwire/view.asp?url=dr-michael-h-gold-joins-aivita-scientific-advisory-board Nashville dermatologist Michael H. Gold, MD, has joined AIVITA Biomedical’s Scientific Advisory Board. His addition comes as AIVITA prepares to launch its upcoming ROOT OF SKINTM line of rejuvenating skincare products. Dr. Gold, the founder of the Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center, and Tennessee Clinical Researcher Center located in Nashville, Tennessee, joins Mary Lupo, MD, founder of the Lupo Center for Aesthetic and General… Fri, 22 Sep 2017 04:00:00 GMT Dove: Women’s Shower Routines May Do More Harm Than Good http://practicaldermatology.com/dermwire/view.asp?url=dove-womens-shower-routines-may-do-more-harm-than-good Close to 80 percent of dermatologists believe women often focus on facial skincare, but neglect body skincare, according to new research from Dove. What’s more, 69 percent of dermatologists report that many women use gentle facial cleansers, but use harsh soap on the rest of their body, and don’t realize the damage they may be doing to their skin in the shower. Fully 86 percent of dermatologists agree that women should be more conscious of the effects of using harsh cleansers on t… Fri, 22 Sep 2017 04:00:00 GMT New Data: Aclaris’ A-101 40% Safely Banishes Facial SK Lesions http://practicaldermatology.com/dermwire/view.asp?url=new-data-aclaris-a-101-40-safely-banishes-facial-sk-lesions Good news for Aclaris. New data suggest that their drug candidate A-101 40 percent may be an appealing option to remove seborrheic keratosis (SK) lesions in highly visible areas, such as the face, with minimal risk of scarring or hypopigmentation. The new findings appear in the journal Dermatologic Surgery. A-101 is an investigational, proprietary, high-concentration hydrogen peroxide-based topical solution that Aclaris is developing as a potential treatment for SK. The FDA’s Prescr… Thu, 21 Sep 2017 04:00:00 GMT New Label Reflects Sustained Response for Sun Pharma’s Odomzo in BCC http://practicaldermatology.com/dermwire/view.asp?url=new-label-reflects-sustained-response-for-sun-pharmas-odomzo-in-bcc Sun Pharma’s new Odomzo® (Sonidegib) label incorporates long-term data showing sustained duration of response of 26 months in treatment of locally advanced basal cell carcinoma. Odomzo® is an oral hedgehog inhibitor indicated for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. It was approved by the US Food and Drug Administr… Wed, 20 Sep 2017 04:00:00 GMT Two-Year Data: TREMFYA™ (guselkumab) Achieves Consistent Rates of Skin Clearance in Moderate to Severe Plaque Psoriasis http://practicaldermatology.com/dermwire/view.asp?url=two-year-data-tremfya-guselkumab-achieves-consistent-rates-of-skin-clearance-in-moderate-to-severe-plaque-psoriasis- New longer-term data from the open-label extension of the VOYAGE 1 trial demonstrate consistent rates of skin clearance with TREMFYA™ treatment through week 100 among patients with moderate to severe plaque psoriasis receiving the subcutaneously administered anti-interleukin (IL)-23 monoclonal antibody. The longer-term findings from the Phase 3 VOYAGE 1 study presented by Janssen Research & Development, LLC (Janssen) at the 26th European Academy of Dermatology and Venereology (EADV) C… Wed, 20 Sep 2017 04:00:00 GMT Eva Genel Named Director of Research and Development, Skincare at Silk Therapeutics http://practicaldermatology.com/dermwire/view.asp?url=eva-genel-named-director-of-research-and-development-skincare-at-silk-therapeutics Eva Genel is the new Director of Research and Development, Skincare at Silk Therapeutics Inc., a specialty biomaterials company. In this new role, Genel's key responsibilities include designing and assessing clean, skincare formulations, overseeing testing, while spearheading innovation, and product development. Genel relocated from Paris, France and is now based in the company's Medford, MA, headquarters, reporting to Greg Altman, CEO of Silk Therapeutics. Genel has more than 15 y… Tue, 19 Sep 2017 04:00:00 GMT SkinCeuticals Launches Two New Cosmeceutical Cleansers http://practicaldermatology.com/dermwire/view.asp?url=skinceuticals-launches-two-new-cosmeceutical-cleansers SkinCeuticals is launching two new cleansers: Replenishing Cleanser and Smoothing Cleanser. What’s more, the original cleansers are all being repacked and reformulated. The new Replenishing Cleanser and Soothing Cleanser join SkinCeuticals's existing cosmeceutical cleanser line, which includes mild cleanser Gentle Cleanser, gel cleanser Simply Clean, exfoliating cleanser LHA Cleanser and cleansing gel Purifying Cleanser, all newly designed with optimized concentrations of active ing… Mon, 18 Sep 2017 04:00:00 GMT U.K Survey Reveals Eczema Treatment Knowledge Gap http://practicaldermatology.com/dermwire/view.asp?url=survey-reveals-eczema-treatment-knowledge-gap Two thirds of UK eczema patients don’t understand that bacteria play a crucial role in their condition despite studies showing that Staphylococcus aureus is present on the skin in of more than 70 percent of patients, according to research from Gladskin. This gap in disease knowledge could be leading to misinformed treatment choices, with 40 percent of the patients not satisfied with their current treatment, and a fifth stating that their symptoms are continuously present. Thirty-seven p… Mon, 18 Sep 2017 04:00:00 GMT EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe AD http://practicaldermatology.com/dermwire/view.asp?url=eadv-news-positive-study-results-for-dupixent-dupilumab-in-patients-with-moderate-to-severe-ad Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to-severe atopic dermatitis (AD) who are inadequately controlled or intolerant to cyclosporine A (CSA), or when this treatment is medically inadvisable, according to results from the Phase 3 CAFÉ study. Regeneron and Sanofi’s Dupixent is a human monoclonal antibody that is designed to … Mon, 18 Sep 2017 04:00:00 GMT Happy 70th Cetaphil! http://practicaldermatology.com/dermwire/view.asp?url=happy-70th-cetaphil Cetaphil is turning 70! To celebrate this milestone birthday, which takes place on Sept. 19, Cetaphil will launch a series of initiatives including: A 70-hour flash sale across retail partners nationwide running from September 17, 2017 at 12:00am EST through September 19, 2017 at 10pm EST. (Consumers can download a $7 coupon directly from coupons.com that will be valid on two or more Cetaphil products within the promotion timeframe.) “Cetaphil Firsts,” a storytelling vide… Fri, 15 Sep 2017 04:00:00 GMT Lilly’s Baricitinib Performs Well in Phase 2 AD Study http://practicaldermatology.com/dermwire/view.asp?url=lillys-baricitinib-performs-well-in-phase-2-ad-study Lilly’s experimental JAK inhibitor Baricitinib in combination with a mid-potency topical corticosteroid (TCS) significantly improved the signs and symptoms of moderate-to-severe atopic dermatitis (AD) compared to TCS alone, with improvements seen as early as first week of treatment. The results of this Phase 2 trial were presented in an oral presentation today at the European Academy of Dermatology and Venereology Annual Meeting in Geneva, Switzerland. Lilly will initiate a Phase 3 cli… Thu, 14 Sep 2017 04:00:00 GMT Vanda's Tradipitant Improves Itch and Disease Severity in AD Patients http://practicaldermatology.com/dermwire/view.asp?url=vandas-tradipitant-improves-itch-and-disease-severity-in-ad-patients Vanda Pharmaceuticals Inc.’s tradipitant improved the intensity of the worst itch patients experienced, as well as atopic dermatitis (AD) disease severity, according to results from an eight-week randomized Phase 2 clinical. Tradipitant is an oral neurokinin-1 receptor (NK-1R) antagonist licensed by Vanda from Eli Lilly and Company (Lilly) in April 2012. Vanda expects to meet with the US Food and Drug Administration in the near future to further define and confirm the clinical develop… Wed, 13 Sep 2017 04:00:00 GMT Five-Year Data Show Sustained Efficacy, Safety for Cosentyx http://practicaldermatology.com/dermwire/view.asp?url=five-year-data-show-sustained-efficacy-safety-for-cosentyx Novartis’ IL-17 blocker Cosentyx® (secukinumab) maintains PASI 90 and PASI 100 response rates at five years in patients with moderate to severe plaque psoriasis, according to new Phase III data. These data were presented for the first time at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland. "Five-year Phase III data are a respected scientific milestone to demonstrate the long-term efficacy and safety of many treatments," says Cra… Wed, 13 Sep 2017 04:00:00 GMT IPC, Others Call for Creation of Worldwide Psoriasis Database http://practicaldermatology.com/dermwire/view.asp?url=ipc-others-call-for-creation-of-worldwide-psoriasis-database A new report calls for the creation of a web-based Global Psoriasis Atlas (GPA) database that will document the prevalence and incidence of psoriasis worldwide. The report, entitled "Global State of Psoriasis Epidemiology: A Workshop Report," appears in the British Journal of Dermatology and is based on a workshop held by the International Psoriasis Council (IPC). The project's first phase, which will begin this year, will be to comprehensively review current psoriasis litera… Wed, 13 Sep 2017 04:00:00 GMT Allergan Adds Coolsculpting, Other Bells and Whistles to Brilliant Distinctions® Patient Loyalty Program http://practicaldermatology.com/dermwire/view.asp?url=allergan-adds-coolsculpting-other-bells-and-whistles-to-brilliant-distinctions-patient-loyalty-program Allergan is launching the next generation of its U.S.-based Brilliant Distinctions® program. The new offering incorporates digital innovation to enhance the consumer experience and drive increased member engagement. In addition, Brilliant Distinctions® is also expanding to include CoolSculpting® in the body treatments category. In the facial aesthetics category, the program provides savings to patients for loyalty and frequency of treatments and products, such as BOTOX® Cos… Tue, 12 Sep 2017 04:00:00 GMT FDA Approves T.R.U.E. Test Ready-To-Use Patch Test for Pediatric Use http://practicaldermatology.com/dermwire/view.asp?url=fda-approves-true-test-ready-to-use-patch-test-for-pediatric-use The FDA has approved SmartPractice's T.R.U.E. TEST (truetest.com) ready-to-use patch test panels for pediatric patients as young as 6 years of age. T.R.U.E. TEST is the only FDA-approved product for diagnosing allergic contact dermatitis (ACD). ACD may affect as many as 20% of the pediatric population (Militello, et al 2006). The most common allergens causing ACD in children are nickel, topical antibiotics, preservative chemicals, fragrances and rubber accelerators. The frequency of ACD t… Tue, 12 Sep 2017 04:00:00 GMT FDA Accepts NDAs for Review of Binimetinib And Encorafenib for Advanced BRAF-mutant Melanoma http://practicaldermatology.com/dermwire/view.asp?url=fda-accepts-ndas-for-review-of-binimetinib-and-encorafenib-for-advanced-braf-mutant-melanoma The FDA has accepted Array BioPharma's New Drug Applications (NDAs) to support use of the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily (COMBO450) for the treatment of patients with BRAF-mutant advanced, unresectable or metastatic melanoma. The FDA set a target action date under the Prescription Drug User Fee Act (PDUFA) of June 30, 2018 for both applications. In addition, the FDA informed Array that based on their preliminary review of the applications they … Tue, 12 Sep 2017 04:00:00 GMT DermTech Appoints Dr. Gerald Krueger to Scientific Advisory Board http://practicaldermatology.com/dermwire/view.asp?url=dermtech-appoints-dr-gerald-krueger-to-scientific-advisory-board DermTech, Inc. has appointed Gerald G. Krueger, MD, to its Scientific Advisory Board. Dr. Krueger is Professor of Dermatology and Edna Benning Presidential Endowed Chair at the University of Utah in Salt Lake City, UT. He received his medical degree from Loma Linda University in Loma Linda, CA, and later completed his residency in dermatology at the University of Colorado. Dr. Krueger is the recipient of the Taub International Award for Psoriasis Research and a National Psoriasis Foundation L… Tue, 12 Sep 2017 04:00:00 GMT Lilly to Present New Data for Olumiant® and Taltz® at EADV http://practicaldermatology.com/dermwire/view.asp?url=lilly-to-present-new-data-for-olumiant-and-taltz-eadv Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation are partners on the development of Olumiant) at the annual European Academy of Dermatology and Venereology Congress (EADV) in Geneva, Switzerland. Lilly will also present data for Taltz® (ixekizumab) from 11 abstracts, including six oral presentations in psoriasis. Highlighted abstracts include… Mon, 11 Sep 2017 04:00:00 GMT Two Galderma Rosacea Therapies Work Well Together http://practicaldermatology.com/dermwire/view.asp?url=two-galderma-rosacea-therapies-work-well-together Combined use of Galderma’s SOOLANTRA (ivermectin1% Cream) and Mirvaso (Brimonidine 0.33% Gel) pack a one-two punch against the erythema and inflammatory lesions of rosacea, the MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea (MOSAIC) study shows. “Concomitant administration of IVM cream with BR gel demonstrated good efficacy and safety, endorsing the comprehensive approach to this complex disease,” the study authors conclude. “Early introdu… Mon, 11 Sep 2017 04:00:00 GMT Deion Sanders Named Brand Ambassador for Botox Cosmetic http://practicaldermatology.com/dermwire/view.asp?url=deion-sanders-named-brand-ambassador-for-botox-cosmetic NFL analyst and philanthropist Deion Sanders, the only athlete to play in both the Super Bowl™ and World Series™, is the new brand ambassador for BOTOX® Cosmetic. Allergan also released two videos featuring Sanders sharing how he addressed his moderate to severe frown lines and crow’s feet with BOTOX® Cosmetic and showing men everywhere how the treatment may be right for them as well. “I’ve always taken pride in my appearance. Turning 50 prompted me to… Fri, 8 Sep 2017 04:00:00 GMT Cemiplimab Receives FDA Breakthrough Therapy Designation for Advanced Cutaneous Squamous Cell Carcinoma http://practicaldermatology.com/dermwire/view.asp?url=cemiplimab-receives-fda-breakthrough-therapy-designation-for-advanced-cutaneous-squamous-cell-carcinoma The FDA has granted Breakthrough Therapy designation status to Regeneron Pharmaceuticals, Inc. and Sanofi's cemiplimab (REGN2810) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (CSCC) and adults with locally advanced and unresectable CSCC. Cemiplimab is an investigational human, monoclonal antibody targeting PD-1. Regeneron and Sanofi previously reported positive, preliminary results for cemiplimab from two expansion cohorts involving 26 advanced CSCC patien… Fri, 8 Sep 2017 04:00:00 GMT Galderma Names New Managers of Prescription Business and Aesthetic Corrective Business Units; Dr. Kelly Huang to Obalon http://practicaldermatology.com/dermwire/view.asp?url=alisa-lask-to-oversee-galdermas-aesthetic--corrective-business-unit-dr-kelly-huang-to-obalon Galdmera has named new managers of its Prescription Business and Aesthetic & Corrective Business units in the United States. Chris Chapman is Galderma’s new Vice President and General Manager of Prescription Business and Alisa Lask is the new Vice President and General Manager of the Aesthetic & Corrective Business Unit. Chris previously served as Vice President of Strategic Access for Galderma’s Prescription Business Unit. In this new role, Chris will manage Galderma'… Thu, 7 Sep 2017 04:00:00 GMT Link Found Between a Molecular Driver of Melanoma Progression and Novel Therapeutic Agent http://practicaldermatology.com/dermwire/view.asp?url=link-found-between-a-molecular-driver-of-melanoma-progression-and-novel-therapeutic-agent Research linking autophagy with the Wnt signaling pathway, a key regulator of melanoma progression and metastasis, may guide effective use of autophagy inhibitors. The findings appear online in Cancer Research. Autophagy allows cancer cells to survive under stressful conditions in the tumor microenvironment. Because it also affects the response to melanoma targeted therapy, several studies are investigating the potential of inhibiting autophagy as a strategy to improve sensitivity to targe… Thu, 7 Sep 2017 04:00:00 GMT